证券之星消息，红日药业(300026)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：上证指数逼近4200点，公司股价却长期徘徊3元区间，4年跌超60%，董秘将其归咎于二级市场波动是否在回避核心问题？核心KB新药IIb期后停滞超6年无III期进展，口服PD-L1临床多年无实质披露，创新药管线全面躺平；业绩严重依赖血必净，配方颗粒受集采下滑，2024年净利暴跌95.76%。请正面回应：1.创新药研发停滞的具体原因？2.如何摆脱单品依赖、扭转业绩颓势？3.将采取哪些可量化的稳股价措施？红日药业回复：您好，公司业务布局可大致分为中药配方颗粒、成品药、医疗器械、原辅料、医疗健康服务和药械智慧供应链。公司在巩固核心产品市场地位的同时，积极推动配方颗粒业务提质增效，以应对集采政策影响。感谢您的关注！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.